» Articles » PMID: 38702613

Structural- and DTI- MRI Enable Automated Prediction of IDH Mutation Status in CNS WHO Grade 2-4 Glioma Patients: a Deep Radiomics Approach

Overview
Journal BMC Med Imaging
Publisher Biomed Central
Specialty Radiology
Date 2024 May 3
PMID 38702613
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The role of isocitrate dehydrogenase (IDH) mutation status for glioma stratification and prognosis is established. While structural magnetic resonance image (MRI) is a promising biomarker, it may not be sufficient for non-invasive characterisation of IDH mutation status. We investigated the diagnostic value of combined diffusion tensor imaging (DTI) and structural MRI enhanced by a deep radiomics approach based on convolutional neural networks (CNNs) and support vector machine (SVM), to determine the IDH mutation status in Central Nervous System World Health Organization (CNS WHO) grade 2-4 gliomas.

Methods: This retrospective study analyzed the DTI-derived fractional anisotropy (FA) and mean diffusivity (MD) images and structural images including fluid attenuated inversion recovery (FLAIR), non-enhanced T1-, and T2-weighted images of 206 treatment-naïve gliomas, including 146 IDH mutant and 60 IDH-wildtype ones. The lesions were manually segmented by experienced neuroradiologists and the masks were applied to the FA and MD maps. Deep radiomics features were extracted from each subject by applying a pre-trained CNN and statistical description. An SVM classifier was applied to predict IDH status using imaging features in combination with demographic data.

Results: We comparatively assessed the CNN-SVM classifier performance in predicting IDH mutation status using standalone and combined structural and DTI-based imaging features. Combined imaging features surpassed stand-alone modalities for the prediction of IDH mutation status [area under the curve (AUC) = 0.846; sensitivity = 0.925; and specificity = 0.567]. Importantly, optimal model performance was noted following the addition of demographic data (patients' age) to structural and DTI imaging features [area under the curve (AUC) = 0.847; sensitivity = 0.911; and specificity = 0.617].

Conclusions: Imaging features derived from DTI-based FA and MD maps combined with structural MRI, have superior diagnostic value to that provided by standalone structural or DTI sequences. In combination with demographic information, this CNN-SVM model offers a further enhanced non-invasive prediction of IDH mutation status in gliomas.

Citing Articles

Modernizing Neuro-Oncology: The Impact of Imaging, Liquid Biopsies, and AI on Diagnosis and Treatment.

Rafanan J, Ghani N, Kazemeini S, Nadeem-Tariq A, Shih R, Vida T Int J Mol Sci. 2025; 26(3).

PMID: 39940686 PMC: 11817476. DOI: 10.3390/ijms26030917.


A Journey into the Complexity of Temporo-Insular Gliomas: Case Report and Literature Review.

Encarnacion Ramirez M, Reyes Soto G, Castillo Rangel C Curr Oncol. 2025; 32(1.

PMID: 39851957 PMC: 11764291. DOI: 10.3390/curroncol32010041.


Cancer neuroscience and glioma: clinical implications.

Westphal M, Drexler R, Maire C, Ricklefs F, Lamszus K Acta Neurochir (Wien). 2025; 167(1):2.

PMID: 39752006 PMC: 11698767. DOI: 10.1007/s00701-024-06406-2.


IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications.

Choate K, Pratt E, Jennings M, Winn R, Mann P Biology (Basel). 2024; 13(11).

PMID: 39596840 PMC: 11592129. DOI: 10.3390/biology13110885.

References
1.
Tan Y, Zhang H, Wang X, Qin J, Wang L, Yang G . Comparing the value of DKI and DTI in detecting isocitrate dehydrogenase genotype of astrocytomas. Clin Radiol. 2019; 74(4):314-320. DOI: 10.1016/j.crad.2018.12.004. View

2.
Prasanna P, Patel J, Partovi S, Madabhushi A, Tiwari P . Radiomic features from the peritumoral brain parenchyma on treatment-naïve multi-parametric MR imaging predict long versus short-term survival in glioblastoma multiforme: Preliminary findings. Eur Radiol. 2016; 27(10):4188-4197. PMC: 5403632. DOI: 10.1007/s00330-016-4637-3. View

3.
Shi D, Savani M, Levitt M, Wang A, Endress J, Bird C . De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. Cancer Cell. 2022; 40(9):939-956.e16. PMC: 9515386. DOI: 10.1016/j.ccell.2022.07.011. View

4.
Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn J, Minniti G . EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2020; 18(3):170-186. PMC: 7904519. DOI: 10.1038/s41571-020-00447-z. View

5.
Wu F, Jiang H, Zheng B, Kogiso M, Yao Y, Zhou C . Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds. J Med Chem. 2015; 58(17):6899-6908. PMC: 4567406. DOI: 10.1021/acs.jmedchem.5b00684. View